{"id":"https://openalex.org/W7225378299","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","title":"1191 Neoadjuvant phase 1b results: dose escalation of intratumoral PH-762 for cutaneous SCC, melanoma, or Merkel cell ( NCT06014086)","display_name":"1191 Neoadjuvant phase 1b results: dose escalation of intratumoral PH-762 for cutaneous SCC, melanoma, or Merkel cell ( NCT06014086)","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225378299","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.1191"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2026-sitc2026.1191","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","pdf_url":"https://jitc.bmj.com/content/14/Suppl_3/A1407.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Late-Breaking Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/14/Suppl_3/A1407.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061743088","display_name":"John Strasswimmer","orcid":"https://orcid.org/0000-0002-5790-2633","observed_orcids":["https://orcid.org/0000-0002-5790-2633"]},"institutions":[{"id":"https://openalex.org/I63772739","display_name":"Florida Atlantic University","ror":"https://ror.org/05p8w6387","country_code":"US","type":"education","lineage":["https://openalex.org/I63772739"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Strasswimmer","raw_affiliation_strings":["Florida Atlantic University, Delray Beach, FL, USA","Integrity Research at Dermatology Assoc. of the Palm Beaches, Inc., Delray Beach, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Atlantic University, Delray Beach, FL, USA","institution_ids":["https://openalex.org/I63772739"]},{"raw_affiliation_string":"Integrity Research at Dermatology Assoc. of the Palm Beaches, Inc., Delray Beach, FL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003452843","display_name":"Mary C. Spellman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary C Spellman","raw_affiliation_strings":["Panclarity LLC, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Panclarity LLC, San Francisco, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104749987","display_name":"Linda Mahoney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210123495","display_name":"Phio Pharmaceuticals (United States)","ror":"https://ror.org/034kn0n30","country_code":"US","type":"company","lineage":["https://openalex.org/I4210123495"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Mahoney","raw_affiliation_strings":["Phio Pharmaceuticals Corp., King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phio Pharmaceuticals Corp., King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210123495"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.95768025,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1407","last_page":"A1408"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9634000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9634000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.024900000542402267,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.8339999914169312},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9760000109672546},{"id":"https://openalex.org/keywords/merkel-cell-carcinoma","display_name":"Merkel cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/skin-cancer","display_name":"skin cancer","score":0.5979999899864197},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6930000185966492},{"id":"https://openalex.org/keywords/sirna-delivery","display_name":"siRNA delivery","score":0.503000020980835},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.6629999876022339},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8209999799728394},{"id":"https://openalex.org/keywords/immune-related-toxicity","display_name":"immune-related toxicity","score":0.5090000033378601},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.4359999895095825}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.785099983215332},{"id":"https://openalex.org/C2778342957","wikidata":"https://www.wikidata.org/wiki/Q1711744","display_name":"Merkel cell carcinoma","level":3,"score":0.6913999915122986},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5716000199317932},{"id":"https://openalex.org/C2780291066","wikidata":"https://www.wikidata.org/wiki/Q1570264","display_name":"Merkel cell","level":4,"score":0.5598999857902527},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.31779998540878296},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.31130000948905945},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2865999937057495},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.26669999957084656},{"id":"https://openalex.org/C2776187983","wikidata":"https://www.wikidata.org/wiki/Q1921796","display_name":"Merkel cell polyomavirus","level":4,"score":0.26570001244544983},{"id":"https://openalex.org/C2993162744","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Skin tumor","level":4,"score":0.2574000060558319},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.25699999928474426}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2026-sitc2026.1191","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","pdf_url":"https://jitc.bmj.com/content/14/Suppl_3/A1407.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Late-Breaking Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2026-sitc2026.1191","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.1191","pdf_url":"https://jitc.bmj.com/content/14/Suppl_3/A1407.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Late-Breaking Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225378299.pdf","grobid_xml":"https://content.openalex.org/works/W7225378299.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4286293108","https://openalex.org/W4308399394","https://openalex.org/W4410816218","https://openalex.org/W4416088141","https://openalex.org/W4401327355","https://openalex.org/W3174955426","https://openalex.org/W4402561443","https://openalex.org/W2080654032","https://openalex.org/W4405165567","https://openalex.org/W4324117901"],"abstract_inverted_index":{"Background":[0],"Systemic":[1],"PD-1":[2,25,30,53,376,397,440,479],"blockade":[3,377,398],"is":[4,13,41],"effective":[5],"but":[6],"may":[7],"cause":[8],"immune-related":[9,211,333],"toxicity.":[10],"1\u20133":[11],"PH-762":[12,97,323,438,489],"a":[14,72,282,297],"self-delivering":[15],"INTASYL-linked":[16],"small":[17],"interfering":[18],"RNA":[19],"(siRNA)":[20],"designed":[21],"to":[22,441,474,477],"silence":[23,478],"the":[24,42,52,99,306,346],"immune":[26,156],"checkpoint":[27],"by":[28,304,315,456],"reducing":[29],"expression":[31],"after":[32],"intratumoral":[33,48,107,319,488],"administration":[34],"(figure":[35],"1).":[36],"To":[37],"our":[38],"knowledge,":[39],"this":[40],"first":[43],"reported":[44],"clinical":[45,171,265,269,485],"demonstration":[46],"of":[47,65,127,215,321],"siRNA":[49,476],"directed":[50],"at":[51,112],"immune-checkpoint":[54],"pathway":[55],"in":[56,80,160,199,205,231,235,240,245,259,271,287,345,380,401,420],"invasive":[57,491],"skin":[58,492],"cancers.4":[59],"We":[60],"report":[61],"final":[62,336],"locked":[63],"analyses":[64],"single-agent":[66,322],"PH-762Methods":[67],"PHIO-762-2301":[68],"(":[69,290],"NCT06014086)":[70],"was":[71,98,167,454],"phase":[73],"1b,":[74],"multicenter,":[75],"open-label,":[76],"noncomparative":[77],"dose-escalation":[78],"study":[79,453],"adults":[81],"with":[82,301,312,378,399],"an":[83],"injectable":[84],"1.0\u20133.0-cm":[85],"cutaneous":[86,382],"squamous":[87],"cell":[88,94],"carcinoma":[89,95],"(cSCC),":[90],"melanoma,":[91,184],"or":[92,117,146,210,221,332],"Merkel":[93],"(MCC).":[96],"sole":[100],"therapeutic":[101],"agent.":[102],"Participants":[103],"received":[104],"four":[105],"weekly":[106,318],"injections":[108],"into":[109],"one":[110],"lesion":[111,295,308],"1.14,":[113],"2.39,":[114],"5.01,":[115],"10.50,":[116],"22.00":[118,275,328],"mg/mL.":[119],"Excision":[120],"on":[121],"day":[122],"36":[123],"enabled":[124],"histologic":[125],"assessment":[126],"residual":[128],"viable":[129,139,144,150],"tumor.":[130],"Pathologic":[131],"responses":[132,172,228,486],"were":[133,173,229,324],"pathologic":[134,169,227,255,283,299,310,342],"complete":[135,268,339],"response":[136,153,239,270,300],"(pCR;":[137],"no":[138,208],"tumor),":[140,145],"near-pCR":[141,234],"(<":[142,148],"10%":[143],"partial":[147,238,298],"50%":[149],"tumor).":[151],"Clinical":[152],"used":[154],"modified":[155],"Response":[157],"Evaluation":[158],"Criteria":[159],"Solid":[161],"Tumors":[162],"(iRECIST).":[163],"The":[164,293,335,349,452],"primary":[165],"endpoint":[166],"safety/tolerability;":[168],"and":[170,202,243,340,352,357,444,484],"secondary":[174],"endpoints.Results":[175],"Twenty-two":[176],"participants":[177,465],"completed":[178],"treatment":[179],"(cSCC,":[180],"n":[181,185,189],"=":[182,186,190],"20;":[183],"1;":[187],"MCC,":[188],"1)":[191],"across":[192],"five":[193],"cohorts.":[194],"Treatment-emergent":[195],"adverse":[196,213,219],"events":[197,204,214],"occurred":[198],"19/22":[200],"(86.4%)":[201],"treatment-related":[203],"11/22":[206],"(50.0%);":[207],"dose-limiting":[209,331],"toxicities,":[212],"special":[216],"interest,":[217],"serious":[218],"events,":[220],"deaths":[222],"occurred.":[223],"Across":[224],"all":[225],"participants,":[226,250],"pCR":[230,258],"9/22":[232],"(40.9%),":[233],"2/22":[236],"(9.1%),":[237],"3/22":[241],"(13.6%),":[242],"nonresponse":[244,311],"8/22":[246],"(36.4%).":[247],"Among":[248],"cSCC":[249],"13/20":[251],"(65.0%)":[252],"had":[253,264,281,296,309],"any":[254],"response,":[256,266,284],"including":[257,267,285,344],"9/20":[260],"(45.0%);":[261],"12/20":[262],"(60.0%)":[263],"3/20":[272],"(15.0%).":[273],"At":[274],"mg/mL":[276],"(all":[277],"cSCC),":[278],"6/7":[279],"(85.7%)":[280],"pCR/near-pCR":[286],"5/7":[288],"(71.4%)":[289],"figure":[291],"2).":[292],"MCC":[294,353],"stable":[302,313],"disease":[303,314],"iRECIST;":[305],"melanoma":[307,351],"iRECISTConclusions":[316],"Four":[317],"doses":[320],"well":[325],"tolerated":[326],"through":[327],"mg/mL,":[329],"without":[330],"toxicities.":[334],"analysis":[337],"documents":[338],"near-complete":[341],"responses,":[343],"highest-dose":[347],"cohort.":[348],"single":[350],"cases":[354],"are":[355],"descriptive":[356],"do":[358],"not":[359],"support":[360],"tumor-specific":[361],"conclusionsTrial":[362],"Registration":[363],"TRIAL":[364],"REGISTRATION":[365],"ClinicalTrials.gov:":[366],"NCT06014086References":[367],"Migden":[368],"MR,":[369],"Rischin":[370],"D,":[371,432],"Schmults":[372],"CD,":[373],"et":[374,395,415,433],"al.":[375,396,416,434],"cemiplimab":[379],"advanced":[381,402,421],"squamous-cell":[383],"carcinoma.":[384,404],"N":[385,405,423],"Engl":[386,406,424],"J":[387,407,425],"Med.":[388,408,426],"2018;379:341\u2013351.Nghiem":[389],"PT,":[390],"Bhatia":[391],"S,":[392],"Lipson":[393],"EJ,":[394],"pembrolizumab":[400],"Merkel-cell":[403],"2016;374:2542\u20132552.Robert":[409],"C,":[410],"Schachter":[411],"J,":[412],"Long":[413],"GV,":[414],"Pembrolizumab":[417],"versus":[418],"ipilimumab":[419],"melanoma.":[422],"2015;372:2521\u20132532.Cuiffo":[427],"B,":[428],"Maxwell":[429],"M,":[430],"Yan":[431],"Self-delivering":[435],"RNAi":[436],"immunotherapeutic":[437],"silences":[439],"generate":[442],"local":[443],"abscopal":[445],"antitumor":[446],"efficacy.":[447],"Front":[448],"Immunol.":[449],"2024;15:1501679.Ethics":[450],"Approval":[451],"approved":[455],"Advarra":[457],"Institutional":[458],"Review":[459],"Board":[460],"(#PRO":[461],"00073270":[462],").":[463],"All":[464],"provided":[466],"written":[467],"informed":[468],"consent.Abstract":[469],"1191":[470,481],"Figure":[471,482],"1INTASYL":[472],"mechanism":[473],"deliver":[475],"expressionAbstract":[480],"2Pathologic":[483],"following":[487],"for":[490],"cancers":[493]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-07T00:00:00"}